ImageneBio's Upcoming Investor Conferences
ImageneBio, Inc. (Nasdaq: IMA), a dynamic player in the biotechnology field, is set to make waves in the fourth quarter with its participation in several notable investor conferences. Based in San Diego, the company specializes in developing advanced therapeutics for patients grappling with immunological, autoimmune, and inflammatory diseases, a mission crucial to enhancing patient outcomes.
Key Conference Details
During the 2025 Stifel Healthcare Conference, ImageneBio will engage in a fireside chat scheduled for Thursday, November 13, at 9:20 AM EST in New York. This event will provide a platform for the company’s management to discuss its innovations and strategic directions.
Following that, on Thursday, December 4, at 10:00 AM EST, ImageneBio will participate in the Piper Sandler 37th Annual Healthcare Conference, where they will share insights on their ongoing projects and future plans. Investors are encouraged to tune in to these sessions to learn about what makes ImageneBio a company to watch.
How to Catch the Webcasts
If you want to catch all the live action from these conferences or view the archived recordings later, you can easily access them through the ImageneBio IR site. This is a great opportunity for investors and interested parties to gain a deeper understanding of the company’s vision and the development of its lead asset, IMG-007.
About ImageneBio, Inc.
ImageneBio is not just any clinical-stage biotechnology firm; it stands at the forefront of innovation, striving to provide groundbreaking solutions for those affected by challenging immunological conditions. Their flagship treatment, IMG-007, is an anti-OX40 monoclonal antibody showcasing unique properties aimed at improving patient care.
The company has made significant progress, having successfully completed Phase 1b/2a trials for IMG-007, focusing on conditions such as atopic dermatitis and alopecia areata. Currently, they are in the midst of a Phase 2b clinical trial specifically for patients experiencing moderate-to-severe atopic dermatitis. This demonstrates their dedication to advancing medical care and finding effective treatments for complex diseases.
Innovation at the Core
ImageneBio’s strategic focus remains anchored in developing therapeutics that are not only effective but also characterized by their innovative approaches. With IMG-007, they target specific immune responses that are critical for managing autoimmune disorders, setting the stage for potentially transformative treatments that could change the lives of many.
Looking Ahead
The future looks promising for ImageneBio as they continue their clinical trials and prepare for upcoming conferences. Their ability to articulate their vision and foster connections with investors and the medical community will be instrumental in driving their initiatives forward. For those interested in the biotech landscape, keeping an eye on ImageneBio and its developments is crucial.
Investor Relations
If you wish to learn more or have inquiries, Investees can reach out directly via their investor and media contact at ir@imagenebio.com. Engaging with the company could provide valuable insights into their projects and vision for the future.
Frequently Asked Questions
What kind of conferences is ImageneBio participating in?
ImageneBio will participate in the Stifel Healthcare Conference and Piper Sandler 37th Annual Healthcare Conference.
What is IMG-007?
IMG-007 is an anti-OX40 monoclonal antibody developed by ImageneBio, targeting autoimmune and inflammatory diseases.
When will the conferences occur?
The Stifel Healthcare Conference is on November 13, and the Piper Sandler Conference is on December 4.
How can I access the conference webcasts?
Live webcasts and archived recordings are available on the ImageneBio IR site.
Who should I contact for more information about ImageneBio?
For additional inquiries, you can contact ImageneBio at ir@imagenebio.com.
